- PA5-50285 - Invitrogen Antibodies NCEH1 antibody

Submitted references KIAA1363 affects retinyl ester turnover in cultured murine and human hepatic stellate cells.

Wagner C, Hois V, Eggeling A, Pusch LM, Pajed L, Starlinger P, Claudel T, Trauner M, Zimmermann R, Taschler U, Lass A
Journal of lipid research 2022 Mar;63(3):100173

Retinoic acid receptor-related orphan receptor α reduces lipid droplets by upregulating neutral cholesterol ester hydrolase 1 in macrophages.

Matsuoka H, Tokunaga R, Katayama M, Hosoda Y, Miya K, Sumi K, Ohishi A, Kamishikiryo J, Shima A, Michihara A
BMC molecular and cell biology 2020 Apr 22;21(1):32

No comments: Submit comment

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemical analysis of NCEH1 in paraffin embedded Human lung cancer tissue using NCEH1 Polyclonal Antibody (Product # PA5-50285) at a 1:80 dilution.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 5 NCEH1 expression is altered in a phorbol 12-myristate 13-acetate (PMA)-dependent manner during macrophage differentiation in THP1 cells. a - d THP1 cells were treated with 50 nM (shaded bars), 100 nM (closed bars), or no PMA (open bars) for 12 h. mRNA expression of RORalpha ( a ), NCEH1 ( b ), CD11b ( c ), and MMP9 ( d ) was analyzed by qRT-PCR, and data were normalized to 18S rRNA levels. Data are means +- standard errors ( n = 4). *, p < 0.05. e THP1 cells were treated with or without 100 nM PMA for 24 h. Protein expression of RORalpha, NCEH1, and GAPDH was analyzed by immunoblot analysis. f Summary of RORalpha and NCEH1 protein levels for each treatment. Data were normalized to GAPDH protein expression. Data are means +- standard errors ( n = 4). *, p < 0.05

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 7 Effects of agonist-induced RORalpha activation on NCEH1 expression. HepG2 cells expressing endogenous RORalpha were treated without (Vehicle, open bars) or with 5 muM SR1078 (closed bars) for 48 or 72 h, and RORalpha ( a ), NCEH1 ( b ), and BMAL1 ( c ) gene expression levels were evaluated. The expression levels of RORalpha-target genes stimulated by the RORalpha agonist are presented as the fold-change relative to those with the vehicle. Data are means +- standard errors ( n = 3). *, p < 0.05. d THP1 cells were treated with 100 nM phorbol 12-myristate 13-acetate (PMA) for 72 h and then treated without or with 5 muM SR1078 for 24 h. Protein expression of NCEH1 and GAPDH was analyzed by immunoblotting. e Summary of NCEH1 protein levels with each treatment. Data were normalized to GAPDH protein expression. Data are means +- standard errors ( n = 4). *, p < 0.05

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Additional file 3. Supplementary figure of immunoblot analysis (Fig. 5 e). THP1 cells were treated with or without 100 nM phorbol 12-myristate 13-acetate (PMA) for 24 h. Protein expression of RORalpha, NCEH1, and GAPDH was analyzed by immunoblot analysis. Molecular weight of RORalpha, NCEH1 and GAPDH are 60, 48 and 37 kDa, respectively.

PA5-50285

Antibody data